Clinical Trial Update: Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC [Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 2 study of the combination of nivolumab and ramucirumab in patients with recurrent, advanced, metastatic non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cyramza (ramucirumab)
• OPDIVO (nivolumab)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING